Bedaquiline and Pyrazinamide Treatment Responses Are Affected by Pulmonary Lesion Heterogeneity in Mycobacterium tuberculosis Infected C3HeB/FeJ Mice

Scott M. Irwin, Brendan Prideaux, Edward R. Lyon, Matthew D. Zimmerman, Elizabeth J. Brooks, Christopher A. Schrupp, Chao Chen, Matthew J. Reichlen, Bryce C. Asay, Martin I. Voskuil, Eric L. Nuermberger, Koen Andries, Michael A. Lyons, Véronique Dartois, Anne J. Lenaerts

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

BALB/c and Swiss mice are routinely used to validate the effectiveness of tuberculosis drug regimens, although these mouse strains fail to develop human-like pulmonary granulomas exhibiting caseous necrosis. Microenvironmental conditions within human granulomas may negatively impact drug efficacy, and this may not be reflected in non-necrotizing lesions found within conventional mouse models. The C3HeB/FeJ mouse model has been increasingly utilized as it develops hypoxic, caseous necrotic granulomas which may more closely mimic the pathophysiological conditions found within human pulmonary granulomas. Here, we examined the treatment response of BALB/c and C3HeB/FeJ mice to bedaquiline (BDQ) and pyrazinamide (PZA) administered singly and in combination. BALB/c mice consistently displayed a highly uniform treatment response to both drugs, while C3HeB/FeJ mice displayed a bimodal response composed of responsive and less-responsive mice. Plasma pharmacokinetic analysis of dissected lesions from BALB/c and C3HeB/FeJ mice revealed that PZA penetrated lesion types from both mouse strains with similar efficiency. However, the pH of the necrotic caseum of C3HeB/FeJ granulomas was determined to be 7.5, which is in the range where PZA is essentially ineffective under standard laboratory in vitro growth conditions. BDQ preferentially accumulated within the highly cellular regions in the lungs of both mouse strains, although it was present at reduced but still biologically relevant concentrations within the central caseum when dosed at 25 mg/kg. The differential treatment response which resulted from the heterogeneous pulmonary pathology in the C3HeB/FeJ mouse model revealed several factors which may impact treatment efficacy, and could be further evaluated in clinical trials. (Figure Presented).

Original languageEnglish (US)
Pages (from-to)251-267
Number of pages17
JournalACS Infectious Diseases
Volume2
Issue number4
DOIs
StatePublished - Apr 8 2016
Externally publishedYes

Fingerprint

bedaquiline
Pyrazinamide
Mycobacterium tuberculosis
Lung
Granuloma
Pharmaceutical Preparations

Keywords

  • bedaquiline
  • C3HeB/FeJ
  • mouse models
  • pyrazinamide
  • tuberculosis

ASJC Scopus subject areas

  • Infectious Diseases

Cite this

Bedaquiline and Pyrazinamide Treatment Responses Are Affected by Pulmonary Lesion Heterogeneity in Mycobacterium tuberculosis Infected C3HeB/FeJ Mice. / Irwin, Scott M.; Prideaux, Brendan; Lyon, Edward R.; Zimmerman, Matthew D.; Brooks, Elizabeth J.; Schrupp, Christopher A.; Chen, Chao; Reichlen, Matthew J.; Asay, Bryce C.; Voskuil, Martin I.; Nuermberger, Eric L.; Andries, Koen; Lyons, Michael A.; Dartois, Véronique; Lenaerts, Anne J.

In: ACS Infectious Diseases, Vol. 2, No. 4, 08.04.2016, p. 251-267.

Research output: Contribution to journalArticle

Irwin, SM, Prideaux, B, Lyon, ER, Zimmerman, MD, Brooks, EJ, Schrupp, CA, Chen, C, Reichlen, MJ, Asay, BC, Voskuil, MI, Nuermberger, EL, Andries, K, Lyons, MA, Dartois, V & Lenaerts, AJ 2016, 'Bedaquiline and Pyrazinamide Treatment Responses Are Affected by Pulmonary Lesion Heterogeneity in Mycobacterium tuberculosis Infected C3HeB/FeJ Mice', ACS Infectious Diseases, vol. 2, no. 4, pp. 251-267. https://doi.org/10.1021/acsinfecdis.5b00127
Irwin, Scott M. ; Prideaux, Brendan ; Lyon, Edward R. ; Zimmerman, Matthew D. ; Brooks, Elizabeth J. ; Schrupp, Christopher A. ; Chen, Chao ; Reichlen, Matthew J. ; Asay, Bryce C. ; Voskuil, Martin I. ; Nuermberger, Eric L. ; Andries, Koen ; Lyons, Michael A. ; Dartois, Véronique ; Lenaerts, Anne J. / Bedaquiline and Pyrazinamide Treatment Responses Are Affected by Pulmonary Lesion Heterogeneity in Mycobacterium tuberculosis Infected C3HeB/FeJ Mice. In: ACS Infectious Diseases. 2016 ; Vol. 2, No. 4. pp. 251-267.
@article{bcd0eaa83eb2407fa9d09d0891e3855d,
title = "Bedaquiline and Pyrazinamide Treatment Responses Are Affected by Pulmonary Lesion Heterogeneity in Mycobacterium tuberculosis Infected C3HeB/FeJ Mice",
abstract = "BALB/c and Swiss mice are routinely used to validate the effectiveness of tuberculosis drug regimens, although these mouse strains fail to develop human-like pulmonary granulomas exhibiting caseous necrosis. Microenvironmental conditions within human granulomas may negatively impact drug efficacy, and this may not be reflected in non-necrotizing lesions found within conventional mouse models. The C3HeB/FeJ mouse model has been increasingly utilized as it develops hypoxic, caseous necrotic granulomas which may more closely mimic the pathophysiological conditions found within human pulmonary granulomas. Here, we examined the treatment response of BALB/c and C3HeB/FeJ mice to bedaquiline (BDQ) and pyrazinamide (PZA) administered singly and in combination. BALB/c mice consistently displayed a highly uniform treatment response to both drugs, while C3HeB/FeJ mice displayed a bimodal response composed of responsive and less-responsive mice. Plasma pharmacokinetic analysis of dissected lesions from BALB/c and C3HeB/FeJ mice revealed that PZA penetrated lesion types from both mouse strains with similar efficiency. However, the pH of the necrotic caseum of C3HeB/FeJ granulomas was determined to be 7.5, which is in the range where PZA is essentially ineffective under standard laboratory in vitro growth conditions. BDQ preferentially accumulated within the highly cellular regions in the lungs of both mouse strains, although it was present at reduced but still biologically relevant concentrations within the central caseum when dosed at 25 mg/kg. The differential treatment response which resulted from the heterogeneous pulmonary pathology in the C3HeB/FeJ mouse model revealed several factors which may impact treatment efficacy, and could be further evaluated in clinical trials. (Figure Presented).",
keywords = "bedaquiline, C3HeB/FeJ, mouse models, pyrazinamide, tuberculosis",
author = "Irwin, {Scott M.} and Brendan Prideaux and Lyon, {Edward R.} and Zimmerman, {Matthew D.} and Brooks, {Elizabeth J.} and Schrupp, {Christopher A.} and Chao Chen and Reichlen, {Matthew J.} and Asay, {Bryce C.} and Voskuil, {Martin I.} and Nuermberger, {Eric L.} and Koen Andries and Lyons, {Michael A.} and V{\'e}ronique Dartois and Lenaerts, {Anne J.}",
year = "2016",
month = "4",
day = "8",
doi = "10.1021/acsinfecdis.5b00127",
language = "English (US)",
volume = "2",
pages = "251--267",
journal = "ACS Infectious Diseases",
issn = "2373-8227",
publisher = "American Chemical Society",
number = "4",

}

TY - JOUR

T1 - Bedaquiline and Pyrazinamide Treatment Responses Are Affected by Pulmonary Lesion Heterogeneity in Mycobacterium tuberculosis Infected C3HeB/FeJ Mice

AU - Irwin, Scott M.

AU - Prideaux, Brendan

AU - Lyon, Edward R.

AU - Zimmerman, Matthew D.

AU - Brooks, Elizabeth J.

AU - Schrupp, Christopher A.

AU - Chen, Chao

AU - Reichlen, Matthew J.

AU - Asay, Bryce C.

AU - Voskuil, Martin I.

AU - Nuermberger, Eric L.

AU - Andries, Koen

AU - Lyons, Michael A.

AU - Dartois, Véronique

AU - Lenaerts, Anne J.

PY - 2016/4/8

Y1 - 2016/4/8

N2 - BALB/c and Swiss mice are routinely used to validate the effectiveness of tuberculosis drug regimens, although these mouse strains fail to develop human-like pulmonary granulomas exhibiting caseous necrosis. Microenvironmental conditions within human granulomas may negatively impact drug efficacy, and this may not be reflected in non-necrotizing lesions found within conventional mouse models. The C3HeB/FeJ mouse model has been increasingly utilized as it develops hypoxic, caseous necrotic granulomas which may more closely mimic the pathophysiological conditions found within human pulmonary granulomas. Here, we examined the treatment response of BALB/c and C3HeB/FeJ mice to bedaquiline (BDQ) and pyrazinamide (PZA) administered singly and in combination. BALB/c mice consistently displayed a highly uniform treatment response to both drugs, while C3HeB/FeJ mice displayed a bimodal response composed of responsive and less-responsive mice. Plasma pharmacokinetic analysis of dissected lesions from BALB/c and C3HeB/FeJ mice revealed that PZA penetrated lesion types from both mouse strains with similar efficiency. However, the pH of the necrotic caseum of C3HeB/FeJ granulomas was determined to be 7.5, which is in the range where PZA is essentially ineffective under standard laboratory in vitro growth conditions. BDQ preferentially accumulated within the highly cellular regions in the lungs of both mouse strains, although it was present at reduced but still biologically relevant concentrations within the central caseum when dosed at 25 mg/kg. The differential treatment response which resulted from the heterogeneous pulmonary pathology in the C3HeB/FeJ mouse model revealed several factors which may impact treatment efficacy, and could be further evaluated in clinical trials. (Figure Presented).

AB - BALB/c and Swiss mice are routinely used to validate the effectiveness of tuberculosis drug regimens, although these mouse strains fail to develop human-like pulmonary granulomas exhibiting caseous necrosis. Microenvironmental conditions within human granulomas may negatively impact drug efficacy, and this may not be reflected in non-necrotizing lesions found within conventional mouse models. The C3HeB/FeJ mouse model has been increasingly utilized as it develops hypoxic, caseous necrotic granulomas which may more closely mimic the pathophysiological conditions found within human pulmonary granulomas. Here, we examined the treatment response of BALB/c and C3HeB/FeJ mice to bedaquiline (BDQ) and pyrazinamide (PZA) administered singly and in combination. BALB/c mice consistently displayed a highly uniform treatment response to both drugs, while C3HeB/FeJ mice displayed a bimodal response composed of responsive and less-responsive mice. Plasma pharmacokinetic analysis of dissected lesions from BALB/c and C3HeB/FeJ mice revealed that PZA penetrated lesion types from both mouse strains with similar efficiency. However, the pH of the necrotic caseum of C3HeB/FeJ granulomas was determined to be 7.5, which is in the range where PZA is essentially ineffective under standard laboratory in vitro growth conditions. BDQ preferentially accumulated within the highly cellular regions in the lungs of both mouse strains, although it was present at reduced but still biologically relevant concentrations within the central caseum when dosed at 25 mg/kg. The differential treatment response which resulted from the heterogeneous pulmonary pathology in the C3HeB/FeJ mouse model revealed several factors which may impact treatment efficacy, and could be further evaluated in clinical trials. (Figure Presented).

KW - bedaquiline

KW - C3HeB/FeJ

KW - mouse models

KW - pyrazinamide

KW - tuberculosis

UR - http://www.scopus.com/inward/record.url?scp=85019538613&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019538613&partnerID=8YFLogxK

U2 - 10.1021/acsinfecdis.5b00127

DO - 10.1021/acsinfecdis.5b00127

M3 - Article

VL - 2

SP - 251

EP - 267

JO - ACS Infectious Diseases

JF - ACS Infectious Diseases

SN - 2373-8227

IS - 4

ER -